Novartis has leased a sizable outpost in the Philadelphia suburbs, according to a local report, settling into the area as it works with University of Pennsylvania researchers on a promising new approach to treating cancer. …read more Source: Novartis sets sights on Philly amid a sweeping CAR-T collaboration
Impax Laboratories is slashing its R&D payroll and moving away from early-stage research, a move designed to save cash in the midst of a costly transition. …read more Source: Impax cans 25% of its R&D staff in a cost-cutting gambit
Novo Nordisk has broken ground on a new R&D shop in its native Denmark, plotting a $130 million project that will expand its wide footprint in diabetes research. …read more Source: Novo Nordisk bets another $130M on diabetes R&D with new Danish hub
…read more Source: Sanofi CEO Viehbacher ousted unanimously by its board
In an uncommon move, the FDA has publicly weighed in on an in-development drug, clarifying the status of Sarepta Therapeutics’ closely watched Duchenne muscular dystrophy treatment eteplirsen in light of an earlier setback that tanked the biotech’s shares. …read more Source: FDA pulls back the curtain on Sarepta’s latest DMD delay
A panel of FDA advisers voted in favor of approving Daiichi Sankyo’s irregular heartbeat treatment edoxaban, heralding its ability to break up blood clots and improving the company’s odds of finally launching the drug in the U.S. …read more Source: Daiichi Sankyo’s new a-fib drug heads toward FDA approval and a crowded market
In this week’s EuroBiotech Report, a who’s who of Big Pharma companies joined a European public-private consortium to develop and test new economic models of antibiotic R&D with the goal of making antibiotic R&D economically attractive again. And more. …read more Source: Big Pharma backs EU antibiotic R&D plan, Pfizer prompts Karo cuts, Advent closes […]
For the now-former chief of Sanofi, Chris Viehbacher, there’s plenty of money for a cushion, but it won’t be nearly as plump as the packages granted to his counterparts in the U.S. …read more Source: Chris Viehbacher leaving Sanofi without a U.S.-style windfall
Cortendo is coming to America. Founded in Sweden, the little biotech has a new CEO who’s building the executive team in the Philadelphia area. And he’s dropping plans for a listing on the Oslo exchange in favor of a U.S. IPO after raising $11 million in bridge financing. …read more Source: Little Cortendo gains $11M […]
AstraZeneca won an FDA nod for a one-pill combination of its latest diabetes drug and the long-generic metformin, making it the second to market among a cadre of drugmakers developing similar cocktails. …read more Source: AstraZeneca wins another diabetes approval in a fast-crowding market
